1. Proton pump inhibitors and H2 receptor antagonists both reduce gastric acid, but they differ fundamentally in the nature of their molecular target interaction. Which statement precisely distinguishes the two classes?
A) Both classes reversibly block the histamine H2 receptor, differing only in potency
B) Proton pump inhibitors form a covalent, irreversible bond with the H+/K+-ATPase, whereas H2 receptor antagonists competitively and reversibly block the histamine H2 receptor
C) Proton pump inhibitors reversibly inhibit the pump, whereas H2 receptor antagonists irreversibly destroy the histamine H2 receptor
D) Both classes covalently inactivate the H+/K+-ATPase at the same cysteine residue
E) Proton pump inhibitors block the muscarinic M3 receptor, whereas H2 receptor antagonists block the gastrin receptor
ANSWER: B
Rationale:
The defining distinction is the target and the reversibility of binding. Proton pump inhibitors act at the terminal effector, the H+/K+-ATPase, forming a covalent disulfide bond with a luminal cysteine residue that irreversibly inactivates the pump; recovery requires synthesis of new pump protein. H2 receptor antagonists act upstream at the histamine H2 receptor, binding competitively and reversibly, so acid secretion resumes once histamine concentrations rise enough to displace the drug.
Option A: Option A is incorrect: only the H2 receptor antagonists act at the H2 receptor; the proton pump inhibitors act at the pump, so the two do not share a single reversible mechanism.
Option C: Option C is incorrect: it reverses the truth — the pump block is irreversible and the receptor block is reversible, not the other way around, and H2 receptor antagonists do not destroy the receptor.
Option D: Option D is incorrect: H2 receptor antagonists do not bind the pump at all, so they cannot share a covalent cysteine interaction with proton pump inhibitors.
Option E: Option E is incorrect: neither class acts primarily at the muscarinic M3 or gastrin receptor — proton pump inhibitors target the pump and H2 receptor antagonists target the H2 receptor.
2. A proton pump inhibitor is administered as one chemical form but does its work as a different form. Which statement correctly identifies the active species and where it is generated?
A) The administered drug is already the active sulfenamide and acts immediately in the bloodstream
B) The active form is generated in the liver by CYP2C19 and circulates to the pump
C) The active form is a reactive aldehyde generated in the small intestine
D) The administered drug is an inactive prodrug that is converted by the acidic canalicular environment into a reactive sulfenamide, which is the species that covalently binds the pump
E) The drug is active as given and is inactivated, rather than activated, at the pump
ANSWER: D
Rationale:
Proton pump inhibitors are administered as inactive substituted benzimidazole prodrugs. They become active only after accumulating in the highly acidic secretory canaliculus of a stimulated parietal cell, where acid catalysis converts them into a reactive sulfenamide. That sulfenamide is the species that forms the covalent disulfide bond with the pump. The requirement for an acidic, actively secreting environment is exactly why the drug concentrates and acts selectively at the pump.
Option A: Option A is incorrect: the administered drug is not the active sulfenamide and does not act in the bloodstream; activation requires the acidic canaliculus.
Option B: Option B is incorrect: CYP2C19 metabolizes and eliminates the drug rather than generating its active form.
Option C: Option C is incorrect: the active species is a sulfenamide formed by acid catalysis at the pump, not an aldehyde formed in the intestine.
Option E: Option E is incorrect: the pump environment activates the prodrug; it is the drug that inactivates the pump, not the pump that inactivates the drug.
3. Among the proton pump inhibitors, one agent is metabolized largely by a route that does not depend on CYP2C19 (cytochrome P450 2C19), making its plasma levels the least affected by CYP2C19 genetic variation. Which agent is this, and what is the route?
A) Rabeprazole, which is cleared predominantly by non-enzymatic reduction rather than by CYP2C19
B) Omeprazole, which is cleared entirely by renal excretion of unchanged drug
C) Pantoprazole, which is not metabolized at all
D) Esomeprazole, which bypasses hepatic metabolism completely
E) Lansoprazole, which is eliminated solely by biliary excretion without metabolism
ANSWER: A
Rationale:
Rabeprazole undergoes substantial non-enzymatic reduction, a pathway independent of CYP2C19, so its exposure is comparatively insensitive to CYP2C19 polymorphism. This is why rabeprazole is favored when consistent acid suppression is needed despite uncertain or variable metabolizer status, such as in Helicobacter pylori eradication in an ultrarapid metabolizer.
Option B: Option B is incorrect: omeprazole is extensively metabolized by CYP2C19, not eliminated unchanged by the kidney.
Option C: Option C is incorrect: pantoprazole is metabolized (it has minimal CYP2C19 inhibitory activity, but it is not unmetabolized); the agent least dependent on CYP2C19 for its own clearance is rabeprazole.
Option D: Option D is incorrect: esomeprazole, the S-enantiomer of omeprazole, still undergoes CYP2C19 metabolism, only somewhat less variably.
Option E: Option E is incorrect: lansoprazole is metabolized by CYP enzymes rather than eliminated solely by biliary excretion of unchanged drug.
4. CYP2C19 (cytochrome P450 2C19) metabolizer status alters proton pump inhibitor exposure. Which statement correctly contrasts a poor metabolizer with an ultrarapid metabolizer?
A) Both phenotypes produce identical plasma exposure; the difference is only theoretical
B) A poor metabolizer clears the drug faster and achieves less acid suppression
C) A poor metabolizer (two loss-of-function alleles) has higher plasma exposure and greater acid suppression, whereas an ultrarapid metabolizer (gain-of-function alleles) clears the drug faster, achieving lower exposure and less suppression
D) An ultrarapid metabolizer has higher exposure and a greater risk of toxicity
E) A poor metabolizer cannot absorb the drug at all
ANSWER: C
Rationale:
Because CYP2C19 eliminates proton pump inhibitors, metabolizer phenotype moves exposure in opposite directions. A poor metabolizer carries two loss-of-function alleles, clears the drug slowly, and therefore has substantially higher plasma exposure and greater acid suppression. An ultrarapid metabolizer carries gain-of-function alleles, clears the drug rapidly, and has lower exposure with less sustained suppression — the phenotype linked to eradication failure at standard doses.
Option A: Option A is incorrect: the phenotypes produce markedly different exposures, which is clinically meaningful.
Option B: Option B is incorrect: it inverts the poor metabolizer, who clears the drug slowly and gets more suppression, not faster clearance and less.
Option D: Option D is incorrect: higher exposure and toxicity risk belong to the poor metabolizer, not the ultrarapid metabolizer.
Option E: Option E is incorrect: poor metabolizer status concerns slowed metabolism, not failure of absorption.
5. Proton pump inhibitors differ in how much they inhibit CYP2C19 (cytochrome P450 2C19), which matters when a patient also takes clopidogrel, a drug that CYP2C19 must activate. Which statement correctly ranks the agents by this inhibitory effect and its clinical consequence?
A) All proton pump inhibitors inhibit CYP2C19 equally, so the choice is irrelevant in a clopidogrel patient
B) Pantoprazole is the strongest CYP2C19 inhibitor and should be avoided with clopidogrel
C) Omeprazole has negligible CYP2C19 inhibition and is the preferred agent with clopidogrel
D) Rabeprazole strongly inhibits CYP2C19 and most reduces clopidogrel activation
E) Omeprazole and esomeprazole significantly inhibit CYP2C19 and can reduce clopidogrel activation, whereas pantoprazole has minimal CYP2C19 inhibition and is the preferred agent when a proton pump inhibitor is needed with clopidogrel
ANSWER: E
Rationale:
The agents are not interchangeable for this interaction. Omeprazole and esomeprazole are meaningful CYP2C19 inhibitors and can blunt the conversion of clopidogrel to its active antiplatelet metabolite. Pantoprazole exerts minimal CYP2C19 inhibition, so it is preferred when a proton pump inhibitor is required alongside clopidogrel and the patient is not at high gastrointestinal bleeding risk.
Option A: Option A is incorrect: the agents differ substantially in CYP2C19 inhibition, so the choice does matter.
Option B: Option B is incorrect: it mislabels pantoprazole — pantoprazole is the low-inhibition, preferred agent, not the strongest inhibitor.
Option C: Option C is incorrect: omeprazole is a significant CYP2C19 inhibitor, the opposite of negligible, and is not the preferred agent here.
Option D: Option D is incorrect: rabeprazole is not characterized as a strong CYP2C19 inhibitor; this option misassigns the strong-inhibitor role.
6. Esomeprazole is chemically related to omeprazole. Which statement correctly defines that relationship?
A) Esomeprazole is a structurally unrelated proton pump inhibitor with a different core ring system
B) Esomeprazole is the S-enantiomer of omeprazole, with somewhat reduced and less variable CYP2C19 (cytochrome P450 2C19) metabolism than the racemic parent
C) Esomeprazole is the inactive R-enantiomer of omeprazole used only as a prodrug reservoir
D) Esomeprazole is an H2 receptor antagonist marketed alongside omeprazole
E) Esomeprazole is a metabolite of omeprazole formed in the liver
ANSWER: B
Rationale:
Esomeprazole is the S-enantiomer of omeprazole, which is a racemic mixture of S- and R-forms. The isolated S-enantiomer undergoes somewhat less, and less variable, CYP2C19 metabolism, giving modestly more consistent exposure than the racemate.
Option A: Option A is incorrect: it is not structurally unrelated — it is one enantiomer of omeprazole and shares the same benzimidazole core.
Option C: Option C is incorrect: esomeprazole is the active S-enantiomer, not the inactive R-form, and it is an active drug rather than a prodrug reservoir.
Option D: Option D is incorrect: esomeprazole is a proton pump inhibitor, not an H2 receptor antagonist.
Option E: Option E is incorrect: esomeprazole is an administered enantiomer of omeprazole, not a hepatic metabolite of it.
7. Cimetidine and famotidine provide comparable acid suppression per equivalent dose, yet famotidine is preferred. Which statement most precisely distinguishes their safety profiles?
A) Cimetidine broadly inhibits multiple CYP isoforms (including CYP1A2, CYP2C9, CYP2D6, and CYP3A4) and blocks androgen receptors at higher doses, whereas famotidine has negligible CYP inhibition and no anti-androgenic effect
B) Famotidine broadly inhibits CYP isoforms, whereas cimetidine has none
C) Both drugs are equally strong CYP inhibitors, differing only in cost
D) Cimetidine has no CYP effects but causes more gynecomastia through a renal mechanism
E) Famotidine blocks androgen receptors, whereas cimetidine does not
ANSWER: A
Rationale:
The discriminating feature is cimetidine's twin liabilities. Cimetidine is a broad inhibitor of several CYP isoforms — CYP1A2, CYP2C9, CYP2D6, and CYP3A4 — raising levels of drugs such as warfarin, theophylline, and phenytoin, and it also blocks androgen receptors at higher doses, producing gynecomastia and sexual dysfunction in men. Famotidine has negligible CYP inhibition and no anti-androgenic activity, which is precisely why it is preferred.
Option B: Option B is incorrect: it reverses the two drugs — the broad CYP inhibition belongs to cimetidine, not famotidine.
Option C: Option C is incorrect: the drugs are not equivalent CYP inhibitors; famotidine's CYP inhibition is negligible.
Option D: Option D is incorrect: cimetidine does inhibit CYP enzymes, and its gynecomastia arises from androgen-receptor blockade, not a renal mechanism.
Option E: Option E is incorrect: the anti-androgenic effect is cimetidine's, not famotidine's.
8. Cimetidine can raise the measured serum creatinine without any true decline in kidney function. Which mechanism precisely accounts for this?
A) Cimetidine is directly nephrotoxic and reduces the GFR (glomerular filtration rate)
B) Cimetidine increases creatinine production by skeletal muscle
C) Cimetidine causes prerenal azotemia through volume depletion
D) Cimetidine blocks the renal tubular secretion of creatinine, raising serum creatinine while the actual GFR (glomerular filtration rate) is unchanged
E) Cimetidine interferes with the laboratory assay, producing a falsely high value with no physiologic basis
ANSWER: D
Rationale:
Creatinine is both filtered at the glomerulus and secreted by the proximal tubule. Cimetidine inhibits that tubular secretion, so less creatinine is cleared by the secretory route and serum creatinine rises, even though glomerular filtration itself is unchanged. Recognizing this prevents misreading the rise as true renal injury.
Option A: Option A is incorrect: the effect is blockade of tubular secretion, not direct nephrotoxicity, and the GFR is not actually reduced.
Option B: Option B is incorrect: cimetidine does not increase muscle creatinine production.
Option C: Option C is incorrect: the rise is not due to volume depletion or prerenal physiology; it is a transport effect at the tubule.
Option E: Option E is incorrect: the rise reflects a real change in creatinine handling in the body, not an in-vitro assay artifact.
9. H2 receptor antagonists and proton pump inhibitors differ in the depth of acid suppression they achieve over 24 hours. Which statement correctly states the difference and the reason for it?
A) H2 receptor antagonists suppress about 90 to 95 percent of 24-hour acidity, more than proton pump inhibitors
B) Both classes suppress roughly the same proportion of acidity, near 75 percent
C) H2 receptor antagonists reduce 24-hour acidity by roughly 60 to 70 percent, less than the 90 to 95 percent achieved by proton pump inhibitors, because reversible blockade of one upstream receptor is less complete than irreversible inactivation of the final pump
D) Proton pump inhibitors suppress less acidity than H2 receptor antagonists because the pump regenerates quickly
E) Neither class reduces 24-hour acidity in a measurable way
ANSWER: C
Rationale:
The magnitudes are characteristically different. H2 receptor antagonists reduce 24-hour intragastric acidity by approximately 60 to 70 percent, while proton pump inhibitors reach approximately 90 to 95 percent. The reason is mechanistic: an H2 receptor antagonist reversibly blocks only the histamine pathway and can be overcome by rising histamine and by the gastrin and acetylcholine inputs, whereas a proton pump inhibitor irreversibly disables the final common effector regardless of which stimulus is driving secretion.
Option A: Option A is incorrect: it inflates H2 receptor antagonist suppression to the proton pump inhibitor range and reverses the ranking.
Option B: Option B is incorrect: the two classes do not suppress acidity equally; the proton pump inhibitor is clearly deeper.
Option D: Option D is incorrect: proton pump inhibitors suppress more, not less, and the irreversibly inhibited pump does not regenerate quickly.
Option E: Option E is incorrect: both classes measurably reduce acidity; the contrast is in degree.
10. Antacid preparations differ in their effect on bowel habit depending on the cation. Which statement correctly matches the cation to its gastrointestinal effect?
A) Aluminum hydroxide is laxative, and magnesium hydroxide is constipating
B) Both aluminum and magnesium salts are constipating
C) Both aluminum and magnesium salts are laxative
D) Calcium carbonate is laxative, which is why it is combined with magnesium
E) Aluminum hydroxide tends to be constipating, magnesium hydroxide tends to be laxative, and combination aluminum-magnesium products are formulated to balance these opposing effects
ANSWER: E
Rationale:
The bowel effect tracks the cation. Aluminum hydroxide tends to cause constipation, while magnesium hydroxide tends to cause diarrhea (it is laxative). Combination aluminum-magnesium antacids are deliberately formulated to offset these opposing tendencies and minimize the net effect on bowel habit.
Option A: Option A is incorrect: it swaps the two — aluminum is constipating and magnesium is laxative, not the reverse.
Option B: Option B is incorrect: magnesium salts are laxative, not constipating.
Option C: Option C is incorrect: aluminum salts are constipating, not laxative.
Option D: Option D is incorrect: the opposing-cation balancing principle here pairs aluminum with magnesium; this option misattributes the laxative effect to calcium carbonate and misstates the combination rationale.
11. One antacid cation is associated with a distinctive syndrome when used in excess over time, and the same agent generates gas with rapid neutralization. Which agent and which syndrome are correctly paired?
A) Aluminum hydroxide and milk-alkali syndrome
B) Calcium carbonate, which can cause the milk-alkali syndrome with excessive chronic use and generates carbon dioxide gas (belching) on neutralization
C) Magnesium hydroxide and milk-alkali syndrome
D) Sodium bicarbonate and aluminum-related osteomalacia
E) Calcium carbonate and disulfiram-like reaction
ANSWER: B
Rationale:
Calcium carbonate is the antacid linked to the milk-alkali syndrome — hypercalcemia, metabolic alkalosis, and renal impairment — when large amounts are taken chronically. It is also rapidly effective but liberates carbon dioxide on reacting with acid, causing belching.
Option A: Option A is incorrect: milk-alkali syndrome is a calcium phenomenon, not an aluminum one.
Option C: Option C is incorrect: magnesium hydroxide is not the cause of milk-alkali syndrome.
Option D: Option D is incorrect: this misattributes the calcium-related syndrome and instead names an unrelated aluminum bone effect with the wrong agent.
Option E: Option E is incorrect: calcium carbonate is correctly named, but its characteristic complication is milk-alkali syndrome, not a disulfiram-like reaction.
12. Sucralfate differs mechanistically from both antacids and the acid-suppressing drugs. Which statement most precisely describes how it works?
A) Below a gastric pH of about 4, sucralfate polymerizes into a viscous adherent paste that binds the protein-rich base of the ulcer crater, forming a physical barrier against acid, pepsin, and bile
B) Sucralfate neutralizes luminal acid through a buffering reaction, like an antacid
C) Sucralfate competitively blocks the histamine H2 receptor
D) Sucralfate irreversibly inactivates the H+/K+-ATPase
E) Sucralfate works only at neutral to alkaline gastric pH and loses activity in acid
ANSWER: A
Rationale:
Sucralfate is an aluminum salt of sucrose octasulfate that requires an acidic environment to act. At a gastric pH below roughly 4 it polymerizes into a sticky, viscous paste that selectively adheres to positively charged proteins at the base of an ulcer crater, creating a protective barrier against acid, pepsin, and bile (and additionally stimulating local prostaglandin, mucus, and bicarbonate production).
Option B: Option B is incorrect: sucralfate does not neutralize acid; that is the antacid mechanism.
Option C: Option C is incorrect: it does not act at the histamine H2 receptor.
Option D: Option D is incorrect: it does not bind or inactivate the pump.
Option E: Option E is incorrect: it is activated by low pH and would not work in an alkaline stomach — the opposite of this statement.
13. Misoprostol is used for NSAID (non-steroidal anti-inflammatory drug) gastroprotection but carries a defining safety restriction. Which statement correctly identifies both its drug class and that restriction?
A) It is an H2 receptor antagonist that is safe throughout pregnancy
B) It is a proton pump inhibitor contraindicated only in renal failure
C) It is a prostaglandin E1 analog with no effect on the uterus
D) It is an antacid whose only limitation is constipation
E) It is a synthetic prostaglandin E1 analog that stimulates uterine contractions and is absolutely contraindicated in pregnancy (Pregnancy Category X)
ANSWER: E
Rationale:
Misoprostol is a synthetic prostaglandin E1 analog. Its defining safety restriction follows directly from that pharmacology: prostaglandin E1 activity stimulates myometrial contractions and cervical ripening, so even the gastroprotective dose can cause miscarriage or preterm labor, making it absolutely contraindicated in pregnancy and assigned Pregnancy Category X.
Option A: Option A is incorrect: it is not an H2 receptor antagonist and is not safe in pregnancy.
Option B: Option B is incorrect: it is not a proton pump inhibitor, and its key restriction is pregnancy, not renal failure.
Option C: Option C is incorrect: it correctly names the prostaglandin E1 class but wrongly denies its uterine effect, which is the entire basis of the contraindication.
Option D: Option D is incorrect: it is not an antacid, and its principal limitation is the pregnancy contraindication, not constipation (its dose-limiting side effect is actually diarrhea).
14. Two common first-line Helicobacter pylori regimens are clarithromycin-based triple therapy and bismuth quadruple therapy. Which statement correctly states their components and the setting that favors the quadruple regimen?
A) Triple therapy is a proton pump inhibitor plus bismuth plus tetracycline; quadruple therapy adds clarithromycin
B) Both regimens contain clarithromycin, so both fail equally when clarithromycin resistance is high
C) Clarithromycin triple therapy is a proton pump inhibitor plus amoxicillin plus clarithromycin; bismuth quadruple therapy is a proton pump inhibitor plus bismuth plus metronidazole plus tetracycline and is favored where clarithromycin resistance is high or prior macrolide exposure has occurred
D) Quadruple therapy omits the proton pump inhibitor to avoid drug interactions
E) Triple therapy is preferred specifically in regions with high clarithromycin resistance
ANSWER: C
Rationale:
Clarithromycin-based triple therapy consists of a proton pump inhibitor plus amoxicillin plus clarithromycin. Bismuth quadruple therapy consists of a proton pump inhibitor plus bismuth plus metronidazole plus tetracycline; because it contains no clarithromycin, it retains high efficacy where clarithromycin resistance is common or where the patient has had prior macrolide exposure, which is exactly the setting that favors it.
Option A: Option A is incorrect: it scrambles the components — triple therapy is the clarithromycin-containing regimen, and quadruple therapy is the bismuth/metronidazole/tetracycline regimen.
Option B: Option B is incorrect: only triple therapy contains clarithromycin, so the two do not fail equally under clarithromycin resistance.
Option D: Option D is incorrect: bismuth quadruple therapy still includes a proton pump inhibitor.
Option E: Option E is incorrect: high clarithromycin resistance favors the bismuth quadruple regimen, not triple therapy.
15. Clarithromycin resistance is the main reason standard triple therapy fails in many regions. What is the precise molecular basis of this resistance in Helicobacter pylori?
A) The bacterium produces an enzyme that hydrolyzes the macrolide ring
B) The bacterium actively pumps clarithromycin out before it reaches the cytoplasm as its sole resistance route
C) Clarithromycin is destroyed by gastric acid before it can act
D) Mutations in the 23S rRNA (ribosomal RNA) gene alter the ribosomal binding site so the macrolide can no longer bind its target
E) The bacterium loses the porin channel required for any antibiotic entry
ANSWER: D
Rationale:
Clarithromycin works by binding bacterial ribosomal RNA to inhibit protein synthesis. Resistance in Helicobacter pylori is principally target-site resistance: point mutations in the 23S rRNA gene change the macrolide binding site so the drug can no longer bind, abolishing its effect. This is why simply increasing the dose does not overcome the resistance.
Option A: Option A is incorrect: macrolide-hydrolyzing enzyme production is not the mechanism described for clarithromycin resistance in this organism.
Option B: Option B is incorrect: the dominant, defined mechanism here is a 23S rRNA target mutation, not an efflux pump acting as the sole route.
Option C: Option C is incorrect: acid degradation is not the basis of clarithromycin resistance.
Option E: Option E is incorrect: generalized porin loss blocking all antibiotic entry is not the described mechanism; resistance is specific target-site alteration.
16. Helicobacter pylori can be assessed with the urea breath test, the stool antigen test, or serology. Which statement correctly discriminates what these tests detect?
A) The urea breath test and stool antigen test detect active infection and can confirm eradication, whereas serology detects antibodies and cannot distinguish active from past infection
B) Serology is the preferred test to confirm successful eradication after treatment
C) The urea breath test detects antibodies, while serology detects active organisms
D) All three tests equally confirm cure immediately after therapy
E) The stool antigen test detects past infection only and cannot indicate active disease
ANSWER: A
Rationale:
The discriminating principle is what each test measures. The urea breath test (which relies on active bacterial urease) and the stool antigen test detect active infection and can therefore be used to confirm eradication after treatment. Serology detects antibodies, which persist for months to years after the organism is gone, so it cannot distinguish active from past infection and should not be used to confirm active infection or cure.
Option B: Option B is incorrect: serology cannot confirm eradication precisely because antibodies remain elevated after successful treatment.
Option C: Option C is incorrect: it reverses the tests — the urea breath test detects active organisms via urease, and serology detects antibodies.
Option D: Option D is incorrect: serology cannot confirm immediate cure, so the three are not equivalent for that purpose.
Option E: Option E is incorrect: the stool antigen test detects active infection, not past infection only.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.